Novo Nordisk announced that Switzerland is the first country to launch Xultophy® (IDegLira) for people with type 2 diabetes.  Xultophy® is the first combination of a basal insulin [Tresiba® (insulin degludec)] and a GLP-1 analogue [Victoza® (liraglutide)]. Xultophy® is administered as a single injection once a day independently of meals.  It is intended for use in adults with type 2 diabetes who are not responding to oral glucose-lowering treatments when they are used alone or together with basal insulin.

For people unable to control their type 2 diabetes with basal insulin, Xultophy® has shown a significant 1.9 percent HbA1c reduction, mean weight loss of 2.7 kg and a low rate of hypoglycemia when compared with insulin degludec.